MSFT reported revenue of $90.0 billion, up 18% year over year, while diluted earnings per share climbed 32% to $4.81. More importantly, Azure and other cloud services accelerated to 43% growth, Microsoft Cloud revenue reached $59.3 billion, and commercial remaining performance obligation expanded to $367 billion. Suggesting that enterprise customers have moved past experimenting with Microsoft’s AI platform and are now committing to it at a scale that can support recurring consumption over multiple years.
Twelve months ago, investors wanted proof MSFT could build the infrastructure needed to lead the AI race. Today, they’re asking whether those investments can produce durable demand before the company spends another $41 billion on capital expenditures next quarter. This earnings report doesn’t answer every question, but it provides the strongest evidence yet that Microsoft’s AI investment cycle is beginning to finance itself
Gold has dipped more than 15% this year. And right now, as you read this sentence, that dip could already be the bottom. Meanwhile, the institutions that print the world's money are dumping their own paper to grab gold at a record pace.
What do they know that the average American doesn't?
Commercial remaining performance obligation climbed to $367 billion, Microsoft Cloud revenue reached $59.3 billion, and Azure accelerated to 43% growth. This commercial backlog is from customers expanding commitments they expect to keep using for years, giving MSFT greater visibility into future revenue while reinforcing the durability of its cloud business.
MSFT wasn’t shy about matching that demand. Capital expenditures surged 70% to $41 billion, with the bulk of the spending directed toward AI infrastructure. Even so, operating income rose 18%, net income climbed 31%, and operating margin held at 45%. Few companies could absorb an infrastructure programmed of that magnitude without compromising profitability. Yet, Microsoft managed to expand both.
Consequently, the market didn’t need long to process the implications as shares climbed nearly 9% after hours, reclaiming the 20-day and 50-day moving averages and moving back above the psychologically important $400 level. The next test sits near the declining 200-day moving average around $434. A decisive move through that level would strengthen the technical picture and reinforce the view that investors are beginning to reward Microsoft’s AI economics rather than simply its AI ambition
Cash Flow Took A Hit And Management Didn’t Blink.
One figure, free cash flow, stood out for all the wrong reasons. It fell 23% to $19.6 billion, a sharp contrast to the company’s otherwise exceptional quarter. On its own, the number looks uncomfortable. The income statement tells a different story.
Operating cash flow climbed 30% to $55.4 billion, while net income reached $35.8 billion. The pressure came from the company’s decision to spend aggressively on data centres, networking equipment and AI hardware. Capital expenditures reached $41 billion, up 70% from a year earlier, with cash paid for property and equipment surging 110% to $35.8 billion.
Management isn’t behaving like a company worried about overbuilding. If anything, it’s signalling the opposite. During the earnings call, executives reiterated that demand for AI infrastructure continues to exceed available capacity, leaving Microsoft in a race to bring more compute online. The willingness to keep investing at this pace reflects confidence that customers will absorb the additional capacity rather than leave it sitting idle.
That investment cycle is unlikely to end soon. The real question for investors is no longer whether Microsoft can afford to spend tens of billions of dollars on AI infrastructure. It’s how long demand can continue outpacing supply. As long as that gap persists, management has little incentive to ease off the accelerator
Marc Chaikin just revealed a powerful strategy — "Sell This, Buy That" — to rid yourself of overpriced AI stocks before a July 31st announcement reshuffles winners and losers.
His "upgrade to Tesla" is a little-known company that just inked a groundbreaking Nvidia partnership — miles ahead of Tesla in the autonomous vehicle race. Plus a Hotlist and Hitlist.
I don’t often increase a position after a stock rallies. More often than not, I prefer buying into pessimism rather than strength. Microsoft is one of the few exceptions.
The investment case no longer rests on promises about what AI might become. Enterprises are embedding it into their operations, and Microsoft has now become the company collecting a cheque every time that happens. That’s a very different business from one selling software licences or productivity tools. It’s an ecosystem where cloud infrastructure, AI models, security and enterprise applications reinforce one another in ways few competitors can replicate.
But I don’t expect the road ahead to be smooth. A company investing this aggressively will always face questions about returns, valuation and execution. And those questions deserve to be asked. However, this quarter shifted the burden of proof. Investors now have stronger reasons to believe Microsoft’s spending is creating durable economic value than reasons to believe it’s becoming excessive.
That’s enough for me to maintain my Buy rating. If my pre-earnings thesis was that Microsoft needed to prove enterprises would make AI part of their everyday workflow, and that it should show up in its Azure consumption and Copilot adoption, this quarter delivered the closest thing to that proof I’ve seen so far.
Just days ago — on July 27th, 2026 — Medicus Pharma Ltd. (NASDAQ: MDCX) cleared a regulatory threshold worth understanding.
The FDA released a "Study May Proceed" letter for SKNJCT-005, authorizing MDCX to launch an NDA-enabling Phase 2b registrational clinical trial of SkinJect® in patients living with Gorlin Syndrome.
This clearance marks a definitive transition from exploratory Phase 2 clinical work into registrational-grade development.
Gorlin Syndrome — additionally known as Nevoid Basal Cell Carcinoma Syndrome — is a rare genetic disorder that subjects patients to an unrelenting cycle of surgical procedures across their lifetime.
Individuals with the condition can develop dozens to more than 1,000 basal cell carcinoma lesions, with onset often occurring as early as childhood or adolescence.
No FDA-approved lesion-directed treatment currently exists for this patient population.
That is the clinical void SkinJect is built to address.
The product is a dissolvable microneedle array patch engineered to deliver doxorubicin chemotherapy directly and precisely into basal cell carcinoma tumors.
Results from prior Phase 2 study SKNJCT-003 — which enrolled 90 patients across nine U.S. sites — showed 64% clinical clearance and 55% histological clearance at Day 57 in the 200 mcg dose group, with no treatment-related serious adverse events reported.
The study established a clear dose-response relationship, generating what the company has called "decision-grade" evidence.
Under SKNJCT-005, up to 50 Gorlin Syndrome patients will be enrolled, with the protocol targeting two to four lesions simultaneously. The FDA's requirement of at least two years of extended patient follow-up is something management has characterized as a protocol enhancement reinforcing durability evaluation — not a limiting condition.
Dr. Raza Bokhari, Executive Chairman and CEO of Medicus Pharma, called the FDA's action "a significant regulatory milestone."
Alongside SkinJect, MDCX is actively advancing Teverelix — a long-acting injectable GnRH antagonist developed for advanced prostate cancer patients carrying elevated cardiovascular risk.
The FDA issued a "Study May Proceed" authorization for a Teverelix Phase 2b dose-optimization study in February 2026, and the company has filed a substantial modification application through the EU Clinical Trials Information System targeting European clinical expansion.
Taken together, the two programs address an estimated$8Bn in addressable markets across multiple indications.
Breaking Down The Company: Medicus Pharma Ltd.
Medicus Pharma Ltd. is a precision-medicine-focused biotech with a presence across three continents.
Its foundational model is a "de-risk and partner" approach: push novel therapeutic assets through Phase 2 proof-of-concept studies, then engage established pharmaceutical partners for licensing or commercialization agreements.
The company joined Nasdaq in January 2025 and celebrated its first year on the exchange with a bell-ringing ceremony on January 22nd, 2026.
SkinJect (D-MNA) — its lead asset — progresses under the FDA's 505(b)(2) regulatory pathway, allowing the company to draw on the established doxorubicin safety record and potentially shorten the regulatory review cycle.
Phase 1 data on Teverelix presented at AACE 2026 confirmed predictable, dose-dependent hormone suppression with no unexpected safety signals.
Active collaborations include a working relationship with Reliant AI Inc. on clinical analytics and a memorandum of understanding with Helix Nanotechnologies targeting mRNA vaccine applications.
(Nasdaq: MDCX) Has 5 Key Potential Catalysts We're Currently Tracking
1). FDA Study May Proceed Letter Puts MDCX On The Registrational Track.
The July 27th, 2026 clearance for SKNJCT-005 positions MDCX as the only company currently advancing a lesion-directed therapy toward an NDA specifically for Gorlin Syndrome — a condition with no FDA-approved lesion-directed treatment today.
2). Orphan Drug Status Application Seeks Seven Years Of Potential Exclusivity.
MDCX submitted an Orphan Drug Designation application in April 2026 for SkinJect in Gorlin Syndrome, which — if granted — would provide MDCX a potential NDA fee exemption exceeding $5Mn and seven years of market exclusivity from the date of FDA approval.
3). Rare Pediatric Disease Designation Request Could Produce A Priority Review Voucher.
Filed in June 2026, the Rare Pediatric Disease Designation request for SkinJect — if awarded — would make MDCX eligible to receive a Priority Review Voucher upon NDA approval, a regulatory instrument with established value in the pharmaceutical licensing market.
4). Dual-Market Regulatory Push Positions Teverelix In The U.S. And Europe.
Having received FDA Phase 2b clearance in February 2026 and submitted for EU clinical expansion through the CTIS platform, MDCX is simultaneously progressing Teverelix across two of the world's largest pharmaceutical markets — targeting a combined addressable market the company pegs at approximately $6Bn.
5). 505(b)(2) Strategy Leverages Existing Doxorubicin Data To Streamline Review.
The FDA's confirmation that SkinJect qualifies for the 505(b)(2) pathway permits MDCX to integrate existing doxorubicin safety information into its NDA submission, a strategic filing advantage that could reduce both regulatory cost and time-to-decision compared to a new chemical entity submission.
Closing Thoughts
Medicus Pharma Ltd. (Nasdaq: MDCX) has not been generating attention without substance behind it.
The announcements this company has made over the past 18 months have consistently carried regulatory or clinical significance: Phase 2 data, FDA clearances, designation applications, conference presentations, and now formal clearance to begin a registrational trial for a rare disease where no approved lesion-directed therapy exists.
That is a pattern worth noting.
If you're tracking the biotech space for names with concrete near-term milestones and a pipeline built on clinical evidence first, MDCX belongs on your radar as 2026 continues to take shape.
We're initiating coverage on Medicus Pharma Ltd. (Nasdaq: MDCX).
Medicus Pharma Ltd. (Nasdaqn: MDCX) received a regulatory authorization on July 27th, 2026, that few market watchers will want to ignore.
The agency issued a "Study May Proceed" letter for SKNJCT-005, granting the company clearance to begin an NDA-enabling Phase 2b registrational clinical trial of SkinJect® in patients with Gorlin Syndrome.
That authorization marks a meaningful step forward — from exploratory Phase 2 evidence into registrational territory.
Gorlin Syndrome, also known as Nevoid Basal Cell Carcinoma Syndrome, is a rare inherited disorder that forces patients into a relentless cycle of surgical interventions.
Those affected can develop dozens to over 1,000 basal cell carcinoma lesions across a lifetime, often beginning in childhood or adolescence.
To date, there is no FDA-approved lesion-directed treatment for this patient population.
The therapy is a dissolvable microneedle array patch that delivers doxorubicin chemotherapy directly into basal cell carcinoma tumors.
Phase 2 data from SKNJCT-003, which enrolled 90 patients at nine U.S. clinical sites, showed 64% clinical clearance and 55% histological clearance at Day 57 in the 200 mcg dose group, with zero treatment-related serious adverse events.
The dataset established a clear dose-response relationship — what the company has described as "decision-grade" evidence.
Registrational study SKNJCT-005 will enroll up to 50 Gorlin Syndrome patients, with treatment targeting two to four lesions at a time. Extended patient follow-up of at least two years is required by the FDA — a protocol enhancement that management views as reinforcing durability evaluation rather than a constraint.
Executive Chairman and Medicus Pharma CEO, Dr. Raza Bokhari, called the clearance "a significant regulatory milestone."
Concurrently, MDCX is advancing Teverelix, a long-acting injectable GnRH antagonist targeting advanced prostate cancer in patients with elevated cardiovascular risk.
The FDA granted"Study May Proceed" clearance for a Teverelix Phase 2b dose-optimization study in February 2026, and the company has filed a substantial modification application through the EU Clinical Trials Information System for a European expansion.
Between the two clinical programs, MDCX estimates approximately $8Bn in total addressable markets across multiple indications.
The therapy is a dissolvable microneedle array patch that delivers doxorubicin chemotherapy directly into basal cell carcinoma tumors.
Phase 2 data from SKNJCT-003, which enrolled 90 patients at nine U.S. clinical sites, showed 64% clinical clearance and 55% histological clearance at Day 57 in the 200 mcg dose group, with zero treatment-related serious adverse events.
The dataset established a clear dose-response relationship — what the company has described as "decision-grade" evidence.
Registrational study SKNJCT-005 will enroll up to 50 Gorlin Syndrome patients, with treatment targeting two to four lesions at a time. Extended patient follow-up of at least two years is required by the FDA — a protocol enhancement that management views as reinforcing durability evaluation rather than a constraint.
Executive Chairman and Medicus Pharma CEO, Dr. Raza Bokhari, called the clearance "a significant regulatory milestone."
Concurrently, MDCX is advancing Teverelix, a long-acting injectable GnRH antagonist targeting advanced prostate cancer in patients with elevated cardiovascular risk.
The FDA granted"Study May Proceed" clearance for a Teverelix Phase 2b dose-optimization study in February 2026, and the company has filed a substantial modification application through the EU Clinical Trials Information System for a European expansion.
Between the two clinical programs, MDCX estimates approximately $8Bn in total addressable markets across multiple indications.
Company Breakdown: Medicus Pharma Ltd.
Medicus Pharma Ltd. is a precision-focused biotech company with operations spanning three continents.
The company follows a "de-risk and partner" model: advance novel therapeutic assets through Phase 2 proof-of-concept clinical trials, then seek licensing or commercialization partnerships with established pharmaceutical companies.
Its lead asset, SkinJect (D-MNA), is being developed under the FDA's 505(b)(2) regulatory pathway, which allows the company to draw on existing doxorubicin safety data and may compress the review timeline.
Teverelix came into the pipeline through the August 2025 acquisition of UK-based Antev Ltd., which added a second late-stage program targeting men with advanced prostate cancer and high cardiovascular risk.
Phase 1 Teverelix data presented at AACE 2026 demonstrated predictable, dose-dependent hormone suppression with no unexpected safety signals.
Strategic collaborations include a partnership with Reliant AI Inc. on clinical analytics and a memorandum of understanding with Helix Nanotechnologies for mRNA vaccine applications.
1. FDA Clearance For Registrational Trial Advances Path Toward NDA Filing. The July 27th, 2026 authorization for SKNJCT-005 positions MDCX as the first company moving a lesion-directed therapy toward a potential NDA submission specifically for Gorlin Syndrome — a condition with no currently approved lesion-directed treatment option.
2. Orphan Drug Application Could Deliver Seven-Year Market Exclusivity. The April 2026 Orphan Drug Designation application for SkinJect in Gorlin Syndrome, if granted, would provide MDCX a potential $5Mn-plus NDA fee exemption alongside seven years of market exclusivity following FDA approval.
3. Rare Pediatric Disease Submission May Unlock A Priority Review Voucher. MDCX filed for Rare Pediatric Disease Designation in June 2026 — a status that, if awarded, could make the company eligible for a Priority Review Voucher upon NDA approval, a regulatory asset with documented value in pharmaceutical licensing transactions.
4. Teverelix Moving Forward On U.S. And European Regulatory Tracks.With FDA Phase 2b clearance secured in February 2026 and an EU regulatory submission filed through the CTIS platform, MDCX is pursuing Teverelix across two major pharmaceutical markets simultaneously, targeting a combined addressable market the company estimates at approximately $6Bn.
5. 505(b)(2) Filing Route May Compress Timelines Versus Standard NDA. The FDA confirmation the 505(b)(2) pathway for SkinJect means MDCX can incorporate existing doxorubicin safety data into its regulatory submission — a structural advantage that may reduce both cost and time-to-decision relative to a new chemical entity pathway.
The Bottom Line
Medicus Pharma Ltd. (Nasdaq: MDCX) isn't making headlines for the sake of it.
Every material announcement from this company over the past 18 months has carried genuine regulatory or clinical substance: Phase 2 data packages, FDA clearances, Orphan Drug applications, conference presentations, and now a registrational trial authorization for a rare disease with no existing approved therapy.
That is a meaningful pattern to recognize.
For those watching the biotech space for names with multiple near-term regulatory milestones and a pipeline built on clinical validation, MDCX is one worth keeping on your radar as 2026 continues to develop.
We are kicking off coverage on Medicus Pharma Ltd. (Nasdaq: MDCX).
Be on the lookout — updates will be heading out soon. Talk again shortly.
